Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company operating in the United States, Europe and other international markets. It trades on Nasdaq under the ticker “VRTX” and is in the Healthcare – Biotech sector. The weekly chart is described as bullish while price stays above the August 2025 low. A move above the November 2024 high is said to confirm a rally in wave (III). Wave ((I)) is placed at $306.08 in July 2020 and wave ((II)) at $176.36 in October 2021. From there, (I) of ((III)) ended at $519.88 in November 2024, and (II) ended at $362.50 in August 2025. Inside (I), the levels are: I $292.75, II $233.01, III $510.63, IV $447.70, V $519.88. Inside III, ((1)) $324.75, ((2)) $282.21, ((3)) $448.40, ((4)) $391.01, ((5)) $510.63. Wave (II) is labelled a double three: w $377.85 in December 2024, x $519.68 in March 2025, y $362.50 in August 2025. After that, ((1)) ended at $507.92, and ((2)) is mapped as a 3- or 7-swing pullback with $463.78 as a referenced high, while a break below the August 2025 low is presented as an alternative risk case. Given the current corrective phase in Vertex Pharmaceuticals, we see this as a period of strategic positioning rather than aggressive buying. The stock remains in a larger bullish trend, but the immediate path points towards a temporary dip to complete its pullback from the highs we saw late last year. This view is supported by the price action since the August 2025 low of $362.50, which remains our key level of support. Looking back, the stock’s run-up to nearly $520 in November 2024 was followed by predictable profit-taking. Recent data reinforces this short-term caution, as Q4 2025 earnings, while strong, were met with a 5% sell-off as guidance was perceived as conservative. Options market data from late February 2026 showed an increase in the put-to-call ratio from 0.6 to 0.9, suggesting traders are positioning for further downside before the next major rally. For the coming weeks, we anticipate a potential short-lived bounce, but this is likely a trap before another move lower. Traders could consider selling call credit spreads with strike prices above the $465 resistance level to capitalize on this expected failure. This strategy profits from both the price decline and time decay during this corrective period. The primary opportunity lies in anticipating the end of this entire corrective sequence. As the stock approaches its projected low, selling cash-secured puts with strike prices in the $380-$400 range could be an effective strategy. This allows traders to collect premium while waiting for a more attractive entry point for a long-term bullish position. We must watch the implied volatility, which has ticked up to around 35%, making option selling strategies more attractive. However, any break below the critical August 2025 low at $362.50 would invalidate this immediate bullish outlook and signal a deeper correction. In that scenario, holding protective puts would be essential for any existing long positions.

Start trading now – Click here to create your real VT Markets account